All Articles
Pharmacist’s Application to Practice: Eflornithine for High-Risk Neuroblastoma
Taylor Gullickson, PharmD, PGY1 Pharmacy Resident and Alexis Kuhn, PharmD, BCOP, Pediatric Oncology Pharmacist, from Mayo Clinic Rochester, Minnesota write about Eflornithine for High-Risk Neuroblastoma.
Late-Breaking HOPA News: COMMANDS Study for Myelodysplastic Syndrome
The COMMANDS study was a phase 3, open-label, multicenter, randomized controlled trial. Patients were eligible for enrollment if they were 18 years or older, diagnosed with very low risk, low risk or intermediate risk MDS, ESA-naïve, and requiring red blo
3 FEATURE Indication Withdrawals of Small Molecule Inhibitors from the Accelerated Approval Program
The United States Food and Drug Administration’s (FDA) Accelerated Approval Program, which expedites approval of drugs and biologics that treat serious conditions such as cancer, has drawn criticism for allowing products to reach the market only to see th